Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 9/20 | 0.32 |
| ▸ | NPY1R | P25929 | 7/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.32 |
| ▸ | NPY2R | P49146 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26329010 | 0.86 | MEN1 (0.33) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL12837508 | 0.84 | NPY4R (0.39) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL13402566 | 0.82 | NPY4R (0.42) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL14199839 | 0.81 | NPY4R (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL9298017 | 0.81 | NPY4R (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL7602596 | 0.79 | NPY4R (0.38) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL14599990 | 0.79 | NPY4R (0.38) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL26757511 | 0.79 | NPY4R (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL18882585 | 0.78 | NPY4R (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL13402556 | 0.78 | NPY4R (0.44) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11060089-B2 | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene | SAREPTA THERAPEUTICS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210169918-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SAREPTA THERAPEUTICS, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210161922-A1 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-06-03 | — | — | US | disclosed |
| US-20200254002-A1 | COMBINATION THERAPIES FOR TREATING MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | US | disclosed |
| US-20200190516-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY | SAREPTA THERAPEUTICS, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-20190284555-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190516-A1 | EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY | MTPN, SMN1; SMN2, UTRN | MEN1 3565/4885CYP1A2 4720/4885KMT2A 3386/4885 |
| US-20190284555-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | GAA, GBA3, GBA1 | MEN1 3977/4885CYP1A2 4595/4885KMT2A 3641/4885 |
| US-11060089-B2 | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene | GAA, GBA3, GBA1 | MEN1 3977/4885CYP1A2 4595/4885KMT2A 3641/4885 |
| US-20200254002-A1 | COMBINATION THERAPIES FOR TREATING MUSCULAR DYSTROPHY | UTRN, MBNL1, TNNC1 | MEN1 4846/4885CYP1A2 4592/4885KMT2A 3249/4885 |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | COL2A1, COL14A1, COL1A1 | MEN1 4699/4885CYP1A2 4805/4885KMT2A 4353/4885 |
| US-20210169918-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | MEN1 3998/4885CYP1A2 4873/4885KMT2A 2078/4885 |
| US-20210161922-A1 | ANTISENSE-INDUCED EXON EXCLUSION IN TYPE VII COLLAGEN | COL2A1, COL14A1, COL1A1 | MEN1 4699/4885CYP1A2 4805/4885KMT2A 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.